These are the 13 most interesting Rapamycin research studies and trials in the longevity field that I keep an extra eye on. The goal is to interview at least one researcher from each of these studies and trials when they are completed. Which of these are your favorite/s?
Here are links to almost all of the above
15 Likes
Pattyg
#2
Hi Kristor, the Pearl study also contains a placebo potential…
1 Like
Yes, good that you point that out! Also many of the other trials have a placebo arm but there was limited space in the image to add that info.
KarlT
#4
So when do we start seeing the results of these studies?
In the end of this year and next year we will start seing more and more human data coming from these studies. After that the off label use will probably start to take off much more and more physicians and researcher will be interested in the field 
3 Likes
JDK
#6
Pearl and the healthspan study is what im looking forward too 
1 Like
Great summary - Thanks for pulling this together in an easy to read visual!
1 Like
In December, 2023 I spoke with Eric Verdin and he told me that the Buck Institute was planning a new Rapamycin clinical trial also. I’ve not heard any updates recently.
Another rapamycin trial is the ME/ CFS clinical trial with rapamycin mentioned at the link below:
2 Likes
Very interesting! Thanks for the update! I will send him a question and see if he answers. Maybe I can also get him reveal his dose regime of Rapamycin
1 Like
JDK
#10
Any hints to when we get the pearl study results?
The last update I heard from AgelessRx is that it will be published in the end of July. So very soon
1 Like
At the December 2024 Longevity Summit at the Buck Institute I spoke with Andrea Maier of the National University of Singapore Longevity group and after two years of ongoing effort to design and organize their rapamycin trial, its finally starting this quarter. Its a six month trial, being done in Singapore on an Asian population, with lots of biomarker analysis (thus the rationale for only a 6 month trial).
So - next year this time we should have some results of this study.
Eric Verdin is still moving forward on the other Rapamycin clinical study - but I didn’t get a chance to talk to him about it, so no update yet on that effort.
3 Likes
Big thanks for letting us now the latest status. I’m very curious how they solved the placebo treatment. Did Andrea mention anything about that because it was quite expensive to get a generic rapamune as placebo?
Yes - we did discuss that. Its one of the reasons it took so long to get this study moving forward. They finally found a company in Italy to provide the rapamycin and the placebo. I have no idea of the cost - but it was one of the many hassles they had. Also the IRB approval took some time. They had issues with figuring out a protocol for if a participant’s glucose or lipids became disregulated when using rapamycin - do they add statin, or metformin, etc. I think they ended up planning for this approach.
1 Like
